

Translational Drug Development Through Functionally Driven Molecular Profiling



Moving your Drug Forward Faster



Vivia Biotech, Credible Science

Lead by Joan Ballesteros in 2000-2006 the founding team developed the PharmaFlow™ Platform.

In 2007 as CSO he was joined....



...by Andres Ballesteros (CEO), together they launched Vivia Biotech in Spain to profile drugs in patient samples & personalize cancer treatments

Vivia provides translational functional and molecular data for your drug and biomarker discovery & development



Vivia Biotech, Proven Value Add

- > 30 Multinational clients: top Pharma (12) and large Biotech's
- > 90 collaborations from preclinical/translational to CDx in clinical trials
- > 160 drugs profiled to date
- > 5,000 patient samples across Hematological Malignancies (HM)
- > 10 year experience working with complex native environment assays

Vivia provides translational functional and molecular data for your drug and biomarker discovery & development

Vivia Biotech, Core Competencies

Native Environment (NE) Portfolio

Standard NE Assays

- Depletion
- Proliferation
- Immuno-oncology
 - Car-T
 - Bi-specific Ab's
 - Imm.Chk,Points
- Phosphoflow

Indications

- AML
- ALL
- MM
- CLL
- CML
- Myelo-fibrosis

Access to Samples

- High quality sample supply & logistics with +60 collaborating hospitals

Treatment & MoA unbiased

- Covers Drugs, Antibodies, or ACTs (Car-T)
- Mechanistically unbiased platform


Unique NE immuno-oncology assays CAR-T, BiTE, & Immune Check Points

PharmaFlow PM + NGS: A Differential Strategy


- Ex-vivo drug sensitivity data by Automated Flow Cytometry
- Unprecedented 93% correct prediction of sensitive patients
- Demonstrated capacity for patient selection & stratification
- Differential approach to molecular biomarker discovery

Key Enabling Translational Technologies

- Providing functional information for selection, go/no go and combination decisions in development
- Incorporating function into molecular discovery to deliver actionable molecular biomarkers as CDx



- Enabling a continuous integrated flow of translational data through the drug & biomarker development path
- Improved understanding of MoA and underlying molecular basis of resistance for early biomarker discovery
- Providing functional information at each development stage to inform decision making for success
- **Enabling functional molecular biomarkers for longitudinal clinical studies from Phase I as CDx**









Vivia Biotech, the Key Enabler for Drug and Biomarker Discovery & Development

Why partner with Vivia Biotech

- Substantial increase of drug efficacy
- Proprietary technology, know-how & validated differential approach
- Unique Native Environment assays
- Align Drug Development with clinical strategy & execution
- Demonstrated capacity to deliver > 80% correlation with treatment outcome translated into clinical CDx through functional NGS
- Unsurpassed access to clinical samples for research
- Unique state of the art immuno-oncology assays for best Car-T selection and IO Drugs

Imagine the value of delivering > 80% response rate in clinical trials?



Your Preferred Partner

For more information, please contact:

Dr Mike Dyson mdyson@viviabiotech.com

David Howard dhoward@viviabiotech.com